161 related articles for article (PubMed ID: 10555157)
1. Antisense strategies to inhibit restenosis.
Lee M; Simon AD; Stein CA; Rabbani LE
Antisense Nucleic Acid Drug Dev; 1999 Oct; 9(5):487-92. PubMed ID: 10555157
[TBL] [Abstract][Full Text] [Related]
2. A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation.
Wang W; Chen HJ; Sun J; Benimetskaya L; Schwartz A; Cannon P; Stein CA; Rabbani LE
Antisense Nucleic Acid Drug Dev; 1998 Jun; 8(3):227-36. PubMed ID: 9669660
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory nonsequence-specific effects of cytidine homopolymers on in vivo neointimal formation.
Wang W; Chen HJ; Schwartz A; Cannon PJ; Stein CA; Rabbani LE
Antisense Nucleic Acid Drug Dev; 1997 Dec; 7(6):559-66. PubMed ID: 9450913
[TBL] [Abstract][Full Text] [Related]
4. Phosphorothioate Oligodeoxynucleotide Inhibition of Restenosis.
Rabbani LE; Wang W
J Thromb Thrombolysis; 1998 May; 5(2):125-128. PubMed ID: 10767106
[TBL] [Abstract][Full Text] [Related]
5. Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides.
Wang W; Chen HJ; Schwartz A; Cannon PJ; Stein CA; Rabbani LE
J Clin Invest; 1996 Jul; 98(2):443-50. PubMed ID: 8755655
[TBL] [Abstract][Full Text] [Related]
6. Porous balloon delivery of S-dC28 does not prevent restenosis in the porcine coronary artery model of balloon injury.
Simon AD; Giedd KN; Schwartz A; Wang W; Sun J; Chen HJ; Marboe C; Stein CA; Rabbani LE
Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):549-53. PubMed ID: 10645782
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen.
Speir E; Epstein SE
Circulation; 1992 Aug; 86(2):538-47. PubMed ID: 1353419
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration.
Biro S; Fu YM; Yu ZX; Epstein SE
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):654-8. PubMed ID: 8421701
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
Bennett MR; Anglin S; McEwan JR; Jagoe R; Newby AC; Evan GI
J Clin Invest; 1994 Feb; 93(2):820-8. PubMed ID: 8113414
[TBL] [Abstract][Full Text] [Related]
10. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury.
Villa AE; Guzman LA; Poptic EJ; Labhasetwar V; D'Souza S; Farrell CL; Plow EF; Levy RJ; DiCorleto PE; Topol EJ
Circ Res; 1995 Apr; 76(4):505-13. PubMed ID: 7895327
[TBL] [Abstract][Full Text] [Related]
11. Temporal expression of c-fos mRNA following balloon injury in the rat common carotid artery.
Mills CJ; Northrup JL; Hullinger TG; Simmons CA; Shebuski RJ; Jones DA
Cardiovasc Res; 1996 Nov; 32(5):954-61. PubMed ID: 8944827
[TBL] [Abstract][Full Text] [Related]
12. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery.
Abe J; Zhou W; Taguchi J; Takuwa N; Miki K; Okazaki H; Kurokawa K; Kumada M; Takuwa Y
Biochem Biophys Res Commun; 1994 Jan; 198(1):16-24. PubMed ID: 8292019
[TBL] [Abstract][Full Text] [Related]
13. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty.
Gunn J; Holt CM; Francis SE; Shepherd L; Grohmann M; Newman CM; Crossman DC; Cumberland DC
Circ Res; 1997 Apr; 80(4):520-31. PubMed ID: 9118483
[TBL] [Abstract][Full Text] [Related]
14. Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury.
Lindner V
Z Kardiol; 1995; 84 Suppl 4():137-44. PubMed ID: 8585266
[TBL] [Abstract][Full Text] [Related]
15. Effects of S-dC28 on vascular smooth muscle cell adhesion and plasminogen activator production.
Wang W; Chen HJ; Warshofsky M; Schwartz A; Stein CA; Rabbani LE
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):101-7. PubMed ID: 9149845
[TBL] [Abstract][Full Text] [Related]
16. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury.
Shi Y; Fard A; Galeo A; Hutchinson HG; Vermani P; Dodge GR; Hall DJ; Shaheen F; Zalewski A
Circulation; 1994 Aug; 90(2):944-51. PubMed ID: 8044966
[TBL] [Abstract][Full Text] [Related]
17. The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific.
Castier Y; Chemla E; Nierat J; Heudes D; Vasseur MA; Rajnoch C; Bruneval P; Carpentier A; Fabiani JN
J Cardiovasc Surg (Torino); 1998 Feb; 39(1):1-7. PubMed ID: 9537527
[TBL] [Abstract][Full Text] [Related]
18. Prevention of ischemically induced neointimal hyperplasia using ex vivo antisense oligodeoxynucleotides.
Poston RS; Tran KP; Mann MJ; Hoyt EG; Dzau VJ; Robbins RC
J Heart Lung Transplant; 1998 Apr; 17(4):349-55. PubMed ID: 9588579
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo antisense oligonucleotides to proliferating cell nuclear antigen and Cdc2 kinase inhibit graft coronary artery disease.
Miniati DN; Hoyt EG; Feeley BT; Poston RS; Robbins RC
Circulation; 2000 Nov; 102(19 Suppl 3):III237-42. PubMed ID: 11082394
[TBL] [Abstract][Full Text] [Related]
20. Sequence-specific antiproliferative effects of antisense and end-capping-modified antisense oligodeoxynucleotides targeted against the 5'-terminus of basic-fibroblast-growth-factor mRNA in coronary smooth muscle cells.
Schmidt A; Sindermann J; Peyman A; Uhlmann E; Will DW; Müller JG; Breithardt G; Buddecke E
Eur J Biochem; 1997 Sep; 248(2):543-9. PubMed ID: 9346314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
